Novel 'Off the Shelf' CAR-T Product Shows Promise in Myeloma

(MedPage Today) -- Use of an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell therapy was feasible and safe and induced responses in patients with relapsed or refractory multiple myeloma, according to interim results from the phase...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news